Novartis Reported Earlier, Its Phase III HARBOR Study Evaluating Del-Desiran In People Living With Myotonic Dystrophy Type 1 Did Not Meet Primary Endpoint

Benzinga Newsdesk www.benzinga.com Negative 78.1%

Neg 78.1% Neu 0% Pos 0%

Comments

No comments yet. Be the first!